Every S-1 that Sunshine Biopharma Inc. (SBFM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow SBFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBFM filings page.
Sunshine Biopharma Inc. is registering a preliminary primary offering of up to $7,000,000, structured as up to 10,180,337 Common Units or substitute Pre-Funded Units on a one-for-one basis. Each Common Unit contains one common share and two Series D Warrants; each Pre-Funded Unit contains one Pre-Funded Warrant for a share plus two Series D Warrants. The registration also covers up to 10,180,337 shares underlying Pre-Funded Warrants and 40,721,348 shares underlying Series D Warrants. The assumed Common Unit price is $0.6876; the final price will be negotiated. Series D Warrants have an initial $0.6876-per-share exercise price and expire five years after issuance; Pre-Funded Warrants have a $0.00001-per-share exercise price.
The best-efforts offering has no minimum closing amount, so actual proceeds may be substantially less than the maximum. Sunshine estimates approximately $6.0 million in net proceeds after placement agent fees and estimated expenses, for general corporate purposes including working capital. Aegis Capital Corp. is the exclusive placement agent, and the offering is expected to end no later than November 30, 2026. Common shares outstanding were 4,310,301 as of October 1, 2026.
Sunshine Biopharma Inc. (SBFM) has filed a Form S-1 to register 25,477,133 shares of common stock issuable upon exercise of its outstanding Series B Warrants. The warrants, issued in a February 15, 2024 public offering, currently have a per share exercise price of $1.2202 and expire on February 15, 2029. The registration is intended to permit the warrants to be exercised for cash rather than on a cashless basis.
If all Series B Warrants are exercised for cash at the current price, Sunshine Biopharma would receive gross proceeds of $31,087,198, or approximately $31 million net, which it plans to use for general corporate purposes, including working capital. The company’s common stock trades on Nasdaq under “SBFM,” with a last reported sale price of $1.27 on August 27, 2026. The prospectus highlights Nasdaq listing risk: the company recently effected multiple reverse stock splits and remains vulnerable to delisting for bid-price noncompliance and to a proposed new $5 million Market Value of Listed Securities requirement that it does not currently meet. Sunshine Biopharma also discloses 29,512,762 outstanding warrants, indicating potential future dilution.
Sunshine Biopharma Inc. has filed an S-1 to offer up to $6,000,000 of common and pre-funded units, including up to 5,825,242 Common Units and associated Series C warrants, on a best efforts basis through Aegis Capital.
Each Common Unit includes one share of common stock and two Series C Warrants with an initial exercise price of $1.03 per share and a five-year term. Alternative Pre-Funded Units substitute a nearly fully paid pre-funded warrant for the common share to help certain investors stay below 4.99% or 9.99% ownership caps. The company estimates net proceeds of about $5.0 million, to be used for general corporate purposes and working capital.
Shares outstanding are expected to increase from 5,005,945 as of May 11, 2026 to 10,831,187 after the assumed full sale of Common Units, before any warrant exercises. Sunshine Biopharma operates a generic drugs business in Canada and is developing oncology and antiviral candidates, including a liver cancer mRNA therapy and a coronavirus protease inhibitor.